NovaBridge Biosciences
Executive Summary
NovaBridge Biosciences is a Shanghai-based biotech with SEC-listed status (ticker: NBP) and clear BIOSECURE designation, making it a potentially viable Chinese partner. However, limited public information on pipeline assets, management team, and recent deal activity suggests either early-stage operations or poor disclosure practices. The company's 20-F filing indicates VIE structure typical of Chinese life sciences companies, requiring careful due diligence on actual operational control and IP ownership.
Structure: As an SEC-listed Chinese biotech, NovaBridge likely operates through a Variable Interest Entity (VIE) structure based on the 20-F filing mentioning VIE disclosures. This structure typically involves a Cayman Islands holding company controlling Chinese operating entities through contractual arrangements rather than direct ownership, which can complicate IP transfers and enforcement in cross-border deals.
Ownership & Shareholder Structure
NovaBridge Biosciences → AbbVie
NovaBridge (formerly I-Mab) lemzoparlimab collaboration with AbbVie.
Corporate Events
NovaBridge Biosciences 20-F Annual Report
20-F annual report filed with SEC. Contains corporate structure, VIE disclosures, and risk factors.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under current restrictions
Key Exposures:
- •VIE structure may involve PRC government influence through contractual parties
- •Shanghai headquarters in region with significant state involvement in biotech sector
Mitigation: Clear BIOSECURE status provides regulatory pathway for US partnerships, though ongoing monitoring required given evolving nature of restrictions
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing activity identified in public sources
Approach: Proceed with cautious initial outreach to assess pipeline and capabilities, given limited public information but favorable regulatory status
Red Flags
- ⚠Minimal public disclosure of pipeline assets and therapeutic focus
- ⚠No identifiable key management team or scientific leadership
- ⚠Limited evidence of operational activity beyond SEC filing requirements
- ⚠Absence of recent news flow or business development activity
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 1
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.